Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript
Summarize this article with:
SA Transcripts159.07K FollowersFollow5ShareSaveCommentsQ4: 2026-03-20 Earnings SummaryPlay CallPlay Call10-KEPS of -$0.15 beats by $0.03 | Revenue of $1.55M beats by $1.55M Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call March 20, 2026 8:30 AM EDT Company Participants Joseph Oliveto - CEO, President & DirectorLorenz Muller - Chief Commercial OfficerAmit Hasija - CFO & Executive VP of Corporate Development Conference Call Participants Michael Wood - Lifesci Advisors, LLCChi Wen Chin - TD Cowen, Research DivisionEdward Tenthoff - Piper Sandler & Co., Research DivisionBrandon Folkes - H.C. Wainwright & Co, LLC, Research DivisionAnthea Li - Jefferies LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Milestone Pharmaceuticals Fourth Quarter and Year-End 2025 Corporate Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I will now turn the call over to your host, Michael Wood of LifeSci Advisors. You may now begin your conference. Michael WoodLifesci Advisors, LLC Thank you, operator, and good morning, everyone, and welcome to the Milestone Pharmaceuticals Full-Year 2025 Financial Results and Business Update Conference Call. Earlier this morning, the company issued a press release providing an overview of its financial results for the year ended December 31, 2025, and recent corporate highlights. The release can be accessed on the Investors and Media section of the company's website, milestonepharma.com. Before I begin, I'd like to remind everyone that some of the information presented on this conference call contains forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause actual clinical programs, future results, progress, timing, performances or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties associated with Milestone's business and factors that could cause or contribute to such differences are described in detail in the company's filings with the SEC, including in the Risk Factors section of the earnings report on Form 10-K